Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing surveillance of AMYViD Injection
jRCT2031220067Active, not recruiting
- Sponsor
- Not Applicable due to Observational Study
- Start
- Mar 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Florbetapir in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD), sponsored by Not Applicable due to Observational Study. Primary endpoint: Safety profile of AMYViD under routine use. Started Mar 2020; status: active, not recruiting.
02
Drugs
Florbetapir
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031220067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220067.